
CTNM Stock Forecast & Price Target
CTNM Analyst Ratings
Bulls say
Contineum Therapeutics Inc. is positioned favorably due to its robust financial foundation, highlighted by cash and equivalents of $190.7 million, which is expected to adequately fund operations through 2027, allowing for the advancement of its promising drug candidates PIPE-791 and PIPE-307. The company's progress in the early stages of clinical trials demonstrates good pharmacokinetics and safety, building confidence as it looks forward to entering Phase II trials in 2025 with backing from an experienced partner. Additionally, the substantial unmet need in multiple sclerosis (MS) indicates that any positive outcomes from the company's candidates could capture significant market interest, enhancing the potential for future growth.
Bears say
Contineum Therapeutics Inc faces significant risks that contribute to a negative outlook for its stock, primarily driven by the potential for developmental setbacks related to its drug candidates, PIPE-791 and PIPE-307. These include the possibility of unexpected safety signals, failure to secure regulatory approvals, and challenges in the commercialization of PIPE-791, particularly given its existing partnership with Johnson & Johnson. Additionally, the company operates without any revenue streams, which raises concerns about its ability to fund ongoing research and development amidst intense competition and operational challenges.
This aggregate rating is based on analysts' research of Contineum Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
CTNM Analyst Forecast & Price Prediction
Start investing in CTNM
Order type
Buy in
Order amount
Est. shares
0 shares